| Serial Number | 79321390 |
| Word Mark | UNISTAC |
| Filing Date | Friday, August 6, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, October 10, 2023 |
| Registration Number | 7184963 |
| Registration Date | Tuesday, October 10, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 21, 2023 |
| Goods and Services | Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases |
| Pseudo Mark | UNI STAC; UNI STACK |
| Goods and Services | Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 5, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 5, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ONEGENE BIOTECHNOLOGY INC. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | ONEGENE BIOTECHNOLOGY INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | ONEGENE BIOTECHNOLOGY INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Tuesday, January 30, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Wednesday, January 10, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Wednesday, January 10, 2024 | FINAL DISPOSITION PROCESSED |
| Wednesday, January 10, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, October 10, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, October 10, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, August 31, 2023 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Monday, March 20, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Friday, March 17, 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Wednesday, March 1, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, March 1, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Tuesday, February 21, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 21, 2023 | PUBLISHED FOR OPPOSITION |
| Monday, February 20, 2023 | NOTIFICATION PROCESSED BY IB |
| Wednesday, February 1, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, February 1, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, February 1, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, January 18, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, December 15, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 14, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 14, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 26, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, October 26, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, October 26, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Wednesday, October 26, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, October 26, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, October 26, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, July 5, 2022 | REFUSAL PROCESSED BY IB |
| Wednesday, June 15, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, June 15, 2022 | REFUSAL PROCESSED BY MPU |
| Friday, May 13, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, May 12, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, May 6, 2022 | ASSIGNED TO EXAMINER |
| Saturday, October 9, 2021 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, October 5, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 30, 2021 | SN ASSIGNED FOR SECT 66A APPL FROM IB |